Abstract
Here we reviewed the recent progress of molecular targeting drugs, including trastuzumab, lapatinib, erlotinib and bevacituzumab. Fortunately, Her-2 positive cases of metastatic or relapsed cases, those with the worse prognosis, are responsive to trastuzumab-based chemotherapy. Lapatinib will likely be effective against trastuzumab-resistant cases and brain metastases. Furthermore, the introduction of bevacituzumab will improve VEGF-VEGFR- associated tumor growth.
MeSH terms
-
Animals
-
Antineoplastic Agents / therapeutic use
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Drug Resistance, Neoplasm
-
Endothelial Cells / metabolism
-
ErbB Receptors / antagonists & inhibitors*
-
ErbB Receptors / metabolism
-
Female
-
HSP90 Heat-Shock Proteins / antagonists & inhibitors
-
HSP90 Heat-Shock Proteins / metabolism
-
Humans
-
Hypoxia-Inducible Factor 1 / antagonists & inhibitors
-
Hypoxia-Inducible Factor 1 / metabolism
-
Lymphangiogenesis
-
Protease Inhibitors / therapeutic use
-
Protein Kinase Inhibitors / therapeutic use
-
Receptor, ErbB-2 / antagonists & inhibitors
-
Receptor, ErbB-2 / metabolism
-
Receptor, IGF Type 1 / antagonists & inhibitors
-
Receptor, IGF Type 1 / metabolism
-
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors*
-
Receptors, Vascular Endothelial Growth Factor / metabolism
-
STAT3 Transcription Factor / metabolism
-
src-Family Kinases / antagonists & inhibitors
-
src-Family Kinases / metabolism
Substances
-
Antineoplastic Agents
-
HSP90 Heat-Shock Proteins
-
Hypoxia-Inducible Factor 1
-
Protease Inhibitors
-
Protein Kinase Inhibitors
-
STAT3 Transcription Factor
-
ErbB Receptors
-
Receptor, ErbB-2
-
Receptor, IGF Type 1
-
Receptors, Vascular Endothelial Growth Factor
-
src-Family Kinases